Home > News > Genevac: Novel Evaporator Technology Produces Reproducibly Large Crystals
Industry Updates New Products Supplier News Upcoming Events business web

Genevac: Novel Evaporator Technology Produces Reproducibly Large Crystals

Hits:1433   Date: 12/12/2014
Genevac: Novel Evaporation Technology Produces Reproducibly Large CrystalsGenevac reports its non-destructive evaporation technology - eXalt has been used by several research groups to produce larger crystals than was previously possible using traditional methods.

Crystallisation is a critical step in the development of many compounds, it can form part of a purification or separation protocol and can influence yield, purity and particle size. Chemists achieve crystallisation by many varied methods. Variation in temperature, solvent, head pressure, seeding method and evaporation rate can all have an effect on the crystallisation process, influencing the form, shape and size of crystals formed. Until the advent of eXalt technology, traditional crystallisation methods have offered little control and often no reproducibility over these parameters.

Genevac's patented eXalt technology enables a wide range of solvents and multiple actives to be evaporated all at the same slow rate, and under the same conditions, giving the user unprecedented control of the crystallisation process. This is achieved using a special holder which can be configured to slow the evaporation rate of each solvent, i.e. the more volatile solvents are impeded more, and some solvents such as water, need no restriction. The holder is then placed in the controlled conditions of a Genevac HT Series Evaporator which cycles the pressure over the samples to create a draw, achieving controlled, even evaporation. eXalt holders can accept up to 24 different samples, and 4 8 or 12 holders can be placed in the evaporator, depending on size.

Areas of application that have particularly benefited from eXalt technology include screening for crystal forms of new compounds, re-crystallisation of existing compounds into new forms, confirmation of stable isomeric forms, production of large seed crystals, co-crystal studies and crystallisation of compounds where only amorphous forms had previously been identified.

For further information please visit www.genevac.com/exalt or contact Genevac on telephone 44-1473-240000 / +44-1473-240000 / +1-845-255-5000 or emailsalesinfo@genevac.co.uk

---------------------
 
Worldwide HQ

Genevac Ltd.
Farthing Road
Ipswich IP1 5AP
UK

tel. +44-1473-240000 
email salesinfo@genevac.co.uk
www.genevac.com 

-----

North America HQ

SP Scientific
3538 Main Street
P.O Box 158
Stone Ridge 
NY 12484
USA

Tel: +1.845.687.5315
e: shireen.scott@spscientific.com